Skip to content

Fractional picosecond 1,064 nanometer laser versus fractional radiofrequency in the treatment of acne scars: a split-face double-blinded randomized control trial

Fractional picosecond 1,064 nanometer laser versus fractional radiofrequency in the treatment of acne scars: a split-face double-blinded randomized control trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210730003
Enrollment
35
Registered
2021-07-30
Start date
2019-06-17
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acne scars (superficial and deep boxcar) fractional picosecond 1,064 nanometer laser, fractional radiofrequency, acne scars

Interventions

fractional picosecond 1,064 nanometer laser 2-4 passes, 0.5-1 J/cm2 every 1 months for 4 times (midface) endpoints: mild petechiae,fractional radiofrequency 2 passes, 25-30 mJ/pin every 1 months for 4
fractional picosecond 1,064 nanometer laser,fractional radiofrequency (fractora)

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with acne scars (superficial and deep boxcar) at face for at least 3 months 2. Fitzpatrick skin type III-V

Exclusion criteria

Exclusion criteria: 1. Patients with photosensitive dermatoses, history of skin cancer, keloid, immunodeficiency, infection/inflammation at the tested area 2. Patients who routinely smoke 3. Pregnancy 4. Receiving acne scars treatment such as AHA, retinoic acid 6 months prior to enrollment 5. Had laser or radiofrequency treatment 3 months prior to enrollment

Design outcomes

Primary

MeasureTime frame
Pore volume Baseline, 1, 3, and 6 months after treatment Antera

Secondary

MeasureTime frame
Volume of skin depression Baseline, 1, 3, and 6 months after treatment Antera,Physician improvement scale Baseline, 1, 3, and 6 months after treatment Quartile scale,Patient improvement scale Baseline, 1, 3, and 6 months after treatment Quartile scale,Melanin index Baseline, 1, 3, and 6 months after treatment Antera,Safety Baseline, 1, 3, and 6 months after treatment Adverse event

Countries

Thailand

Contacts

Public ContactThanya Techapichetvanich

Faculty of Medicine Siriraj Hospital, Mahidol University

thanya.tec@gmail.com66837122248

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026